19-12897776-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000159.4(GCDH):c.1156C>T(p.Arg386*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000161 in 1,613,868 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000159.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GCDH | NM_000159.4 | c.1156C>T | p.Arg386* | stop_gained | 11/12 | ENST00000222214.10 | NP_000150.1 | |
GCDH | NM_013976.5 | c.1156C>T | p.Arg386* | stop_gained | 11/12 | NP_039663.1 | ||
GCDH | NR_102316.1 | n.1319C>T | non_coding_transcript_exon_variant | 11/12 | ||||
GCDH | NR_102317.1 | n.1537C>T | non_coding_transcript_exon_variant | 10/11 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GCDH | ENST00000222214.10 | c.1156C>T | p.Arg386* | stop_gained | 11/12 | 1 | NM_000159.4 | ENSP00000222214.4 |
Frequencies
GnomAD3 genomes AF: 0.00000658 AC: 1AN: 152084Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.00000795 AC: 2AN: 251468Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135914
GnomAD4 exome AF: 0.0000171 AC: 25AN: 1461784Hom.: 0 Cov.: 32 AF XY: 0.0000179 AC XY: 13AN XY: 727202
GnomAD4 genome AF: 0.00000658 AC: 1AN: 152084Hom.: 0 Cov.: 31 AF XY: 0.0000135 AC XY: 1AN XY: 74286
ClinVar
Submissions by phenotype
Glutaric aciduria, type 1 Pathogenic:9
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Feb 12, 2019 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Lifecell International Pvt. Ltd | - | A Heterozygous Nonsense variant c.1156C>T in Exon 11 of the GCDH gene that results in the amino acid substitution p.Arg386* was identified. The observed variant has a minor allele frequency of 0.00001/0.00003% in gnomAD exomes and genomes, respectively. The severity of the impact of this variant on the protein is high, based on the effect of the protein and REVEL score . Rare Exome Variant Ensemble Learner (REVEL) is an ensembl method for predicting the pathogenicity of missense variants based on a combination of scores from 13 individual tools: MutPred, FATHMM v2.3, VEST 3.0, PolyPhen-2, SIFT, PROVEAN, MutationAssessor, MutationTaster, LRT, GERP++, SiPhy, phyloP, and phastCons. The REVEL score for an individual missense variant can range from 0 to 1, with higher scores reflecting greater likelihood that the variant is disease-causing. ClinVar has also classified this variant as Pathogenic(variant ID: 235616). This variant has been observed in many individuals affected with Glutaricaciduria, type I reported by (Kölker S et al., 2007). Based on the above evidence this variant has been classified as Pathogenic according to the ACMG guidelines. - |
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Sep 12, 2018 | The GCDH c.1156C>T (p.Arg386Ter) variant is a stop-gained variant that is predicted to result in a premature termination of the protein. The p.Arg386Ter variant has been reported in four studies and is found in at least four probands with glutaric acidemia including two in a homozygous state, two in a compound heterozygous state, and two in a heterozygous state without an identified second allele (Biery et al. 1996; Zschocke et al. 2000; Christensen et al. 2004; Tsai et al. 2017). Control data are unavailable for the p.Arg386Ter variant, which is reported at a frequency of 0.000011 in the Total population of the Genome Aggregation Database. Expression analysis in E. coli and fibroblasts found the p.Arg386Ter variant exhibited a greater than 95% reduction in GCD activity (Biery et al. 1996; Christensen et al. 2004). Due to the potential impact of stop-gained variants, the p.Arg386Ter variant is classified as pathogenic for glutaric acidemia. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 29, 2023 | This sequence change creates a premature translational stop signal (p.Arg386*) in the GCDH gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GCDH are known to be pathogenic (PMID: 10699052, 11854167, 16602100). This variant is present in population databases (rs752127949, gnomAD 0.003%). This premature translational stop signal has been observed in individuals with glutaric aciduria type I (PMID: 8900227, 15505393, 28302372). ClinVar contains an entry for this variant (Variation ID: 235616). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 06, 2018 | Variant summary: GCDH c.1156C>T (p.Arg386X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 1.1e-05 in 277140 control chromosomes (gnomAD). The variant, c.1156C>T has been reported in the literature in multiple individuals affected with Glutaric Acidemia Type 1 (Biery_1996, Christensen_2004, Koker_2007). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in <10% of normal activity (Christensen_2004). A ClinVar submission from another clinical diagnostic laboratory (evaluation after 2014) cite the variant as "pathogenic." Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Sep 27, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 20, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Suma Genomics | - | - - |
Hypomyelinating leukodystrophy 2 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Kasturba Medical College, Manipal, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, India | - | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics | Oct 05, 2017 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at